Skip to content

Pancreatic cancer mRNA vaccine shows durable responses in early trial

scienceApr 19, 202626524

A personalized mRNA vaccine tailored to each patient’s tumor mutations produced durable responses in a small phase I trial for pancreatic cancer. Nearly all patients WHO responded to the vaccine remained alive six years after treatment. The study was early-stage and small, and researchers say larger randomized trials are required to determine whether the vaccine can improve survival for more patients.

Key Highlights

Personalized mRNA vaccine matched to patients' tumor mutations in phase I trial
Nearly all responders remained alive six years after treatment
Larger randomized trials are needed to confirm survival benefit
1 source